Pancreatic serous cystadenoma related mortality is almost nil

Jaïs, Bénédicte; Rebours, Vinciane; Malleo, Giuseppe; Salvia, Roberto; Kim, Myung–Hwan; Ha, Yeonjung; Marchegiani, Giovanni; Castillo, Carlos Fernández‐del; Jang, Jin–Young; Kim, Sun‐Whe; Crippa, Stefano; Falconi, Massimo; Milanetto, Anna Caterina; Sperti, Cosimo; Ricci, Claudio; Casadei, Riccardo; Delhaye, Myriam; Bernier, Benjamin; Chiaro, Marco Del; Segersvärd, Ralf; Gomatos, Ilias P.; Neoptolemos, John P.; Huggett, Matthew T.; Oppong, Kofi; Pererva, L.; Kopchak, Kostiantyn; Osvaldt, Alessandro Bersch; Campos, Vinícius Jardim; Lévy, Philippe

doi:10.1016/j.pan.2014.05.392

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are a number of different pancreatic cysts and lesions which demand varying treatment protocols. For example, benign and inflammatory pancreatic cysts with no malignant potential, including pseudocysts, inflammatory masses, and serous cystadenomas (SCA) [ 3 ], have either no risk or a very low risk of malignant change, and asymptomatic lesions can be managed conservatively with long-term follow-up. Whereas mucinous lesions, like mucinous cystic neoplasms (MCN) and intraductal papillary mucinous neoplasms (IPMN), are considered pre-malignant lesions and require more careful consideration.…”

Section: Introductionmentioning

confidence: 99%

Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies

et al. 2016

View full text Add to dashboard Cite

BackgroundPancreatic ductal adenocarcinoma (PDAC) is a lethal disease. Novel biomarkers are required to aid treatment decisions and improve patient outcomes. MicroRNAs (miRNAs) are potentially ideal diagnostic biomarkers, as they are stable molecules, and tumour and tissue specific.ResultsLogistic regression analysis revealed an endoscopic-ultrasound fine-needle aspiration (EUS-FNA) 2-miRNA classifier (miR-21 + miR-155) capable of distinguishing benign from malignant pancreatic lesions with a sensitivity of 81.5% and a specificity of 85.7% (AUC 0.930). Validation FNA cohorts confirmed both miRNAs were overexpressed in malignant disease, while circulating miRNAs performed poorly.MethodsFifty-five patients with a suspicious pancreatic lesion on cross-sectional imaging were evaluated by EUS-FNA. At echo-endoscopy, the first part of the FNA was sent for cytological assessment and the second part was used for total RNA extraction. Candidate miRNAs were selected after careful review of the literature and expression was quantified by qRT-PCR. Validation was performed on an independent cohort of EUS-FNAs, as well as formalin-fixed paraffin embedded (FFPE) and plasma samples.ConclusionsWe provide further evidence for using miRNAs as diagnostic biomarkers for pancreatic malignancy. We demonstrate the feasibility of using fresh EUS-FNAs to establish miRNA-based signatures unique to pancreatic malignant transformation and the potential to enhance risk stratification and selection for surgery.

show abstract

Section: Introductionmentioning

confidence: 99%